Immuneering 경영진
경영진 기준 점검 4/4
Immuneering CEO는 Ben Zeskind, Feb2008 에 임명되었습니다 의 임기는 18.5 년입니다. 총 연간 보상은 $1.66M, 38.6% 급여 및 61.4% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $16.90M 가치에 해당하는 회사 주식의 4.96% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 4.4 년과 5 년입니다.
핵심 정보
Ben Zeskind
최고경영자
US$1.7m
총 보수
| CEO 급여 비율 | 38.63% |
| CEO 재임 기간 | 18.5yrs |
| CEO 지분 보유율 | 5.0% |
| 경영진 평균 재임 기간 | 4.4yrs |
| 이사회 평균 재임 기간 | 5yrs |
최근 경영진 업데이트
Recent updates
Seeking Alpha • Jul 27
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Summary Immuneering Corporation targets first-line pancreatic cancer with atebimetinib, showing promising Phase 2a results versus standard-of-care regimens. IMRX's pivotal Phase 3 trial in first-line PDAC is recruiting, with first patient dosing expected mid-2026 and cash runway projected into 2029. Atebimetinib demonstrated median overall survival of 17.3 months, outperforming historical controls and comparing favorably to competitors’ data. Despite strong clinical data and differentiated tolerability, IMRX trades at a deep discount to peers, presenting a high-risk, high-reward opportunity. Read the full article on Seeking Alpha분석 기사 • Jun 30
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
새로운 내러티브 • Mar 19
Pancreatic Cancer Breakthrough And Long Patent Tail Will Transform This Oncology Platform
Catalysts About Immuneering Immuneering is a biotechnology company focused on developing atebimetinib, a MEK inhibitor, for cancers driven by the MAP kinase pathway, with an initial focus on first line pancreatic cancer and expansion into lung cancer and other tumor types. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Mar 05
Pivotal Pancreatic Cancer Trial And Extended Patent Protection Will Shape A Long Runway
Catalysts About Immuneering Immuneering is a clinical stage biotech company focused on developing atebimetinib, a MEK inhibitor, for cancers driven by the MAP kinase pathway, with an initial focus on first line pancreatic cancer and expansion into lung cancer. What are the underlying business or industry changes driving this perspective?분석 기사 • Nov 22
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Immuneering...분석 기사 • Jul 01
Here's Why Immuneering (NASDAQ:IMRX) Must Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Mar 18
Immuneering (NASDAQ:IMRX) Will Have To Spend Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...분석 기사 • Aug 30
Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • May 13
Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Mar 19
Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
Summary Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024. IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024. Immuneering had $85.7 million in cash as of December 31st of 2023; Enough cash to fund its operations into the 2nd half of 2025. Read the full article on Seeking Alpha분석 기사 • Jan 06
Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Aug 17
We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Sep 30
Immuneering wins FDA nod to study lead asset in solid tumors
The development-stage biotech Immuneering Corporation (NASDAQ:IMRX) announced Friday that the FDA greenlighted its Investigational New Drug (IND) application to study IMM-1-104, its lead candidate targeted at advanced RAS mutant solid tumors. Accordingly, the company expects to begin a Phase 1/2a clinical trial to assess the oral, once-daily therapy in advanced RAS mutant solid tumors across five clinical sites in the U.S. IMRX expects to follow the Phase 1 segment of the study with a dose expansion Phase 2a portion targeted at RAS mutated pancreatic, melanoma, colorectal, and lung cancers. The first patient is expected to enroll in Q4 2022. “Clearance of the IND for IMM-1-104 brings us one step closer to our goal of developing medicines with the potential to benefit every cancer patient with a RAS mutant solid tumor, not just those harboring specific mutations,” Chief Executive Ben Zeskind said. The announcement of the IND submission for IMM-1-104 sent IMRX shares higher early this month.Seeking Alpha • Sep 02
Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate
The shares of development-stage biotech Immuneering Corporation (NASDAQ:IMRX) added ~9% in the pre-market trading Friday after the company announced the filing of an Investigational New Drug (IND) seeking FDA clearance to conduct a clinical trial for its lead asset IMM-1-104. An oral once-daily small molecule, IMM-1-104, targets advanced solid tumors with RAS mutations, unlike the candidates that target specific cancer mutations such as KRAS-G12C. “The preclinical data package for IMM-1-104 is uniquely compelling, and we are excited to now evaluate this compound in patients who so urgently need new options,” the Chief Executive of IMRX, Brett Hall, noted. With the IND submission, the FDA will review the company’s application to determine if the data support the safety of IMM-1-104. IMRX plans to conduct a Phase 1/2a clinical trial of IMM-1-104 across five internationally recognized clinical sites in the U.S. Amgen (AMGN) and Mirati Therapeutics (MRTX) are among the developers of cancer therapies targeted at KRAS G12C mutations.Seeking Alpha • Jul 08
Immuneering initiated a Buy by Chardan, PT set to $18
Immuneering (NASDAQ:IMRX) initiated with a Buy by Chardan analyst Geulah Livshits and gave $18 as price target. The analyst likes the potential of Immuneering's pipeline and translational bioinformatics platform to address unmet needs in diverse cancers. The company's approach integrates analysis of high-throughput transcriptional, genomics, and proteomics datasets to generate insights into tumor signaling dynamics, and mechanisms of therapy response or resistance, to advance drug candidates with optimal signaling profiles, Livshits tells investors in a research note. Currently, the stock is trading at $6.3, a rise of ~10.7% on Friday. Stock has slumped about 64% over the last one year and company has a market cap of $139M . The stock is given a Wall Street 'Strong Buy' rating with 4.5 score (4 Strong Buy, 1 Buy, 1 Hold) Comparative rating of the stock against the peers:CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$57m |
| Mar 31 2026 | n/a | n/a | -US$54m |
| Dec 31 2025 | US$2m | US$641k | -US$56m |
| Sep 30 2025 | n/a | n/a | -US$62m |
| Jun 30 2025 | n/a | n/a | -US$62m |
| Mar 31 2025 | n/a | n/a | -US$62m |
| Dec 31 2024 | US$2m | US$617k | -US$61m |
| Sep 30 2024 | n/a | n/a | -US$58m |
| Jun 30 2024 | n/a | n/a | -US$56m |
| Mar 31 2024 | n/a | n/a | -US$54m |
| Dec 31 2023 | US$2m | US$593k | -US$53m |
| Sep 30 2023 | n/a | n/a | -US$52m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$51m |
| Dec 31 2022 | US$2m | US$570k | -US$51m |
| Sep 30 2022 | n/a | n/a | -US$48m |
| Jun 30 2022 | n/a | n/a | -US$44m |
| Mar 31 2022 | n/a | n/a | -US$40m |
| Dec 31 2021 | US$2m | US$400k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$29m |
| Jun 30 2021 | n/a | n/a | -US$24m |
| Mar 31 2021 | n/a | n/a | -US$20m |
| Dec 31 2020 | US$806k | US$293k | -US$17m |
보상 대 시장: Ben의 총 보수(USD1.66M)는 US 시장에서 비슷한 규모 기업의 평균(USD2.41M)보다 낮습니다.
보상과 수익: Ben의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Ben Zeskind (43 yo)
18.5yrs
재임 기간
US$1,660,612
보수
Dr. Benjamin J. Zeskind, also known as Ben, Ph D., MBA serves as the Co-Founder, President, Chief Executive Officer and Director of Immuneering Corporation since February 2008 and served as its Secretary....
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 18.5yrs | US$1.66m | 4.96% $ 16.9m | |
| Co-Founder & Chair Emeritus | 18.6yrs | US$93.52k | 1.78% $ 6.0m | |
| Chief Scientific Officer | 6.8yrs | US$1.29m | 0.59% $ 2.0m | |
| Chief Legal Officer & Secretary | 5.1yrs | US$890.36k | 0.0075% $ 25.6k | |
| CFO & Treasurer | less than a year | 데이터 없음 | 0.35% $ 1.2m | |
| Senior Director of Accounting & Operations and Assistant Corporate Controller | 4.9yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP of Finance | 4yrs | 데이터 없음 | 0.043% $ 145.0k | |
| Director of Quality Systems & Compliance | less than a year | 데이터 없음 | 데이터 없음 | |
| Vice President of Corporate Communications | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief People Officer | 3.8yrs | 데이터 없음 | 0.046% $ 155.8k | |
| Head of Discovery & VP | no data | 데이터 없음 | 데이터 없음 | |
| Head of Translational Pharmacology & VP | 4.4yrs | 데이터 없음 | 데이터 없음 |
4.4yrs
평균 재임 기간
54yo
평균 나이
경험이 풍부한 관리: IMRX의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.4 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 18.5yrs | US$1.66m | 4.96% $ 16.9m | |
| Co-Founder & Chair Emeritus | 17.3yrs | US$93.52k | 1.78% $ 6.0m | |
| Independent Director | 5.4yrs | US$106.81k | 0.022% $ 73.7k | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Chairman of the Board | 2.4yrs | US$104.89k | 0.12% $ 392.4k | |
| Director | 5.6yrs | US$103.38k | 1.79% $ 6.1m | |
| Member of Pancreatic Cancer Advisory Board | 1.7yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 4.6yrs | US$101.52k | 0.0085% $ 29.0k | |
| Member of Pancreatic Cancer Advisory Board | 1.7yrs | 데이터 없음 | 데이터 없음 |
5.0yrs
평균 재임 기간
66yo
평균 나이
경험이 풍부한 이사회: IMRX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/21 10:25 |
| 종가 | 2026/08/20 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Immuneering Corporation는 11명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Andres Maldonado | H.C. Wainwright & Co. |